Hikma launches first ritonavir generic in USA

20 March 2018

Jordan-based Hikma Pharmaceuticals (LSE: HIK) says that its wholly-owned US subsidiary West-Ward Pharmaceuticals, has launched ritonavir tablets USP, 100mg, the first AB-rated generic to Norvir tablets.

According to the Food and Drug Administraton product approval letter, West-Ward is eligible for 180 days of generic drug exclusivity.

West-Ward’s ritonavir, a copy of US pharma major AbbVie’s (NYSE: ABBV) Norvir, is approved by the FDA for use in combination with other antiretroviral agents for treatment of human immunodeficiency virus (HIV-1) infection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK